2024-09-03 - Analysis Report
## Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases.

**1. Performance vs. S&P 500:**

* **REGN Cumulative Return:** 159.56%
* **VOO (S&P 500) Cumulative Return:** 89.66%
* **Difference:** 69.90% (Relative Strength: 95.82%)

REGN has significantly outperformed the S&P 500, with a 69.90% higher cumulative return. This strong performance places it at the 95.82 percentile of its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $1184.69
* **5-day Moving Average:** $1192.81
* **20-day Moving Average:** $1158.30
* **60-day Moving Average:** $1090.18

The stock price is currently below its 5-day moving average, indicating a slight downward trend in the short term. However, it remains above its 20-day and 60-day moving averages, suggesting a more positive medium to long-term outlook.

**3. Technical Indicators:**

* **RSI:** 73.51
* **PPO:** -0.17
* **Delta_Previous_Relative_Divergence:** -4.18 (Short-term downward trend)
* **Expected Return:** 3.13% (Potential 5-year return on investment)

The RSI value indicates that the stock is currently in overbought territory. The negative PPO value signals a potential slowdown in momentum. The negative Delta_Previous_Relative_Divergence suggests a short-term downward trend in relative performance. However, the Expected Return remains positive, indicating potential for future growth.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | $3.55 B |
| 2024-05-02 | 6.7 | $3.15 B |
| 2023-11-02 | 9.48 | $3.36 B |
| 2023-08-03 | 9.05 | $3.16 B |
| 2024-08-01 | 9.05 | $3.16 B |

The latest earnings report showed strong revenue and EPS growth, exceeding analysts' expectations. Regeneron is expected to continue its strong performance, driven by its diverse pipeline and successful existing products.

**5. Overall Analysis:**

REGN has demonstrated exceptional growth and outperformance compared to the S&P 500. While short-term indicators suggest a potential slowdown in momentum, the company's strong financials, diverse pipeline, and positive future outlook warrant further investigation. The stock remains attractive for long-term investors with a moderate to high risk tolerance.

**6. Key Takeaways:**

* REGN has a strong track record of outperforming the market.
* Recent price action suggests a possible short-term correction.
* Strong earnings and future prospects support a positive long-term outlook.
* Technical indicators point towards a potential slowdown in momentum.
* Investors should carefully consider their risk tolerance before investing.
